Revvity (NYSE:RVTY) Lowered to "Hold" Rating by Wall Street Zen

Revvity (NYSE:RVTY - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Other equities analysts also recently issued reports about the company. KeyCorp raised their price objective on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Barclays lowered their price objective on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. UBS Group upgraded shares of Revvity from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $145.00 to $115.00 in a research note on Thursday, May 1st. Robert W. Baird dropped their price objective on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 29th. Finally, Raymond James reiterated an "outperform" rating and set a $120.00 price objective (down previously from $145.00) on shares of Revvity in a research note on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $125.64.

Revvity Trading Up 0.5%

NYSE RVTY traded up $0.48 during trading hours on Friday, hitting $91.82. 1,101,887 shares of the company's stock were exchanged, compared to its average volume of 954,851. The business's 50 day moving average is $95.35 and its 200-day moving average is $108.44. Revvity has a 12-month low of $88.01 and a 12-month high of $129.50. The firm has a market capitalization of $10.82 billion, a P/E ratio of 41.55, a price-to-earnings-growth ratio of 3.82 and a beta of 1.02. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. The company had revenue of $664.76 million for the quarter, compared to the consensus estimate of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The company's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $0.98 EPS. As a group, analysts anticipate that Revvity will post 4.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Revvity

A number of large investors have recently added to or reduced their stakes in RVTY. Assetmark Inc. boosted its position in Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after purchasing an additional 259 shares during the period. Optiver Holding B.V. acquired a new position in shares of Revvity during the fourth quarter worth approximately $33,000. Quarry LP lifted its holdings in shares of Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after buying an additional 95 shares during the last quarter. Millstone Evans Group LLC acquired a new position in shares of Revvity during the fourth quarter worth approximately $38,000. Finally, Vermillion Wealth Management Inc. acquired a new position in shares of Revvity during the fourth quarter worth approximately $41,000. Institutional investors own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.